NCT07264101 Validity And Reliability Of The Four Square Step Test In Individuals With Rheumatoid Arthritis
| NCT ID | NCT07264101 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inonu University |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-12-15 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This cross-sectional observational study aims to evaluate the validity and reliability of the Four Square Step Test (FSST) in individuals with rheumatoid arthritis. In addition, the study will investigate the associations between FSST performance and clinical parameters including disease activity, quality of life, pain, and muscle strength. All assessments will be conducted according to a pre-defined standardized protocol. The order of measurement tools will be randomized to minimize potential bias, and sufficient rest intervals will be provided between tests to prevent fatigue and performance effects. Participants will include individuals aged 18-65 years with a diagnosis of rheumatoid arthritis according to the ACR/EULAR 2010 classification criteria, who have been followed for at least 6 months, have had no major changes in treatment regimen in the last 4 weeks (e.g., initiation or change of DMARDs/biologics, high-dose steroid increase), can walk at least 10 meters independently, have a Mini-Mental State Examination score of 24 or higher, and are able to follow verbal instructions in Turkish to comply with study procedures. Appropriate statistical methods will be applied to assess validity, reliability, and associations between FSST and clinical parameters.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 years * Diagnosis of rheumatoid arthritis according to ACR/EULAR 2010 criteria * No major changes in treatment regimen (e.g., initiation or modification of DMARDs/biologics, high-dose steroid increase) within the last 4 weeks * Ability to walk at least 10 meters without assistance * Mini-Mental State Examination (MMSE) score ≥ 24 * Ability to understand and follow instructions in Turkish Exclusion Criteria: * Participants who cannot understand or follow verbal instructions in Turkish * Participants with a history of neurological, vestibular, or serious orthopedic disease * Participants whose physical participation is limited due to acute infection or systemic disease * Participants who have had lower extremity surgery or a history of serious injury within the last 6 months
Contact & Investigator
Zeynal Yasacı
PRINCIPAL INVESTIGATOR
Inonü University
Frequently Asked Questions
Who can join the NCT07264101 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07264101 currently recruiting?
Yes, NCT07264101 is actively recruiting participants. Contact the research team at eminetonak4006@gmail.com for enrollment information.
Where is the NCT07264101 trial being conducted?
This trial is being conducted at Malatya, Turkey (Türkiye).
Who is sponsoring the NCT07264101 clinical trial?
NCT07264101 is sponsored by Inonu University. The principal investigator is Zeynal Yasacı at Inonü University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.